Accessibility Menu
 
Cyclerion Therapeutics logo

Cyclerion Therapeutics

(NASDAQ) CYCN

Current Price$3.17
Market Cap$14.12M
Since IPO (2019)-99%
5 Year-93%
1 Year-1%
1 Month-49%

Cyclerion Therapeutics Financials at a Glance

Market Cap

$14.12M

Revenue (TTM)

$2.07M

Net Income (TTM)

$3.53M

EPS (TTM)

$-1.18

P/E Ratio

-2.77

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$3.17

Volume

754

Open

$3.24

Previous Close

$3.26

Daily Range

$3.16 - $3.24

52-Week Range

$1.03 - $8.48

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cyclerion Therapeutics

Industry

Biotechnology

Employees

1

CEO

Regina Graul, PhD

Headquarters

Cambridge, MA 02142, US

CYCN Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-39%

Return on Capital

-55%

Return on Assets

-35%

Earnings Yield

-36.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.12M

Shares Outstanding

4.33M

Volume

754

Avg. Volume

4.58M

Financials (TTM)

Gross Profit

$2.07M

Operating Income

$4.97M

EBITDA

$4.97M

Operating Cash Flow

$3.31M

Capital Expenditure

$0.00

Free Cash Flow

$3.31M

Cash & ST Invst.

$3.24M

Total Debt

$0.00

Cyclerion Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.02M

-43.2%

Gross Profit

$1.02M

-43.2%

Gross Margin

100.00%

N/A

Market Cap

$14.12M

N/A

Market Cap/Employee

$14.12M

N/A

Employees

1

N/A

Net Income

$799.00K

-250.8%

EBITDA

$838.00K

-266.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$3.24M

+0.2%

Accounts Receivable

$1.00M

+79.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-35.33%

N/A

Return on Invested Capital

-54.74%

N/A

Free Cash Flow

$1.58M

-538.6%

Operating Cash Flow

$1.58M

-538.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PLRZPolyrizon Ltd.
$15.39-3.81%
VYNEVYNE Therapeutics Inc.
$0.66+2.45%
XTLBXTL Biopharmaceuticals Ltd.
$3.89+6.50%
KTTAPasithea Therapeutics Corp.
$0.87+3.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
CNSPCns Pharmaceuticals
$8.93+2.86%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.79+0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$50.85+0.01%
ADTADT
$7.03-0.07%

Questions About CYCN

What is the current price of Cyclerion Therapeutics?

Cyclerion Therapeutics is trading at $3.18 per share.

What is the 52-week range for Cyclerion Therapeutics?

Over the past 52 weeks, Cyclerion Therapeutics has traded between $1.03 and $8.48.

How much debt does Cyclerion Therapeutics have?

As of the most recent reporting period, Cyclerion Therapeutics reported total debt of N/A.

How much cash does Cyclerion Therapeutics have on hand?

Cyclerion Therapeutics reported $3.24M in cash and cash equivalents in its most recent financial results.

What is Cyclerion Therapeutics’s dividend yield?

Cyclerion Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.